Showing results (151-160 of 189) with videos related to

Sort By:
Pageof 19
Medical Oncology (Northwood, London, England)|September 17, 2009
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGETS Negrier, E Jäger, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2009
Malignant peritoneal mesothelioma: a multicenter study on 81 casesV de Pangher Manzini, L Recchia, M Cafferata, et al.
Investigational New Drugs|July 14, 2005
BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR)R-D Hofheinz, C Porta, G Hartung, et al.
ESMO Open|October 30, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysisF Salani, F R Ponziani, F Piscaglia, et al.
International Journal of Cancer|March 14, 2007
Erionite and asbestos differently cause transformation of human mesothelial cellsP Bertino, A Marconi, L Palumbo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2006
Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxisD Fagnani, R Franchi, C Porta, et al.
Cancer Treatment Reviews|January 15, 2015
PD-1 blockade therapy in renal cell carcinoma: current studies and future promisesF Massari, M Santoni, C Ciccarese, et al.
Contrast Media & Molecular Imaging|May 4, 2019
Prognostic Value of <sup>18</sup>F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with DocetaxelE Quaquarini, D D'Ambrosio, F Sottotetti, et al.
Journal of Cellular Physiology|August 15, 2000
Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitroC Porta, M Danova, A M Orengo, et al.
British Journal of Cancer|March 24, 2012
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysisS Bracarda, T E Hutson, C Porta, et al.
Pageof 19